FDA Drug Review, Surveillance Offices To Share Authority Over Safety
This article was originally published in The Tan Sheet
Executive Summary
FDA's drug review and drug safety offices set aside their differences in an agreement to more equally divide regulatory authority on drug safety issues
You may also be interested in...
FDA Contract Explores Quantified Risk/Benefit Approach
FDA is exploring the idea of a more formal, quantitative system for assessing the risk/benefit of drugs
FDA Contract Explores Quantified Risk/Benefit Approach
FDA is exploring the idea of a more formal, quantitative system for assessing the risk/benefit of drugs
FDA Contract Explores Quantified Risk/Benefit Approach
FDA is exploring the idea of a more formal, quantitative system for assessing the risk/benefit of drugs